Daily non-political popular news in brief.
AVN944 inhibits IMPDH & induces apoptosis-related biomarkers in patients with hematologic cancers
12-11-2006 · EurekAlert!IMPDH is highly upregulated in most hematological cancers and solid tumors -- an essential role in cancer cell synthesis of DNA and RNA. Inhibition of IMPDH represents a new and important approach to treat cancer. In a Phase I trial of AVN944, AvalonRx identified a set of 34 genes. These gene markers correlate with the biochemical effects of AVN944 on protein function -- believed to result in tumor cell apoptosis at the right doses.
Read more »
Keywords: avn944, inhibits, impdh, induces, apoptosis-related, biomarkers, patients, hematologic, cancers, inhibit, induce, apoptosis, related, biomarker, patient, cancer
« Previous | Next »
Similar news on "AVN944 inhibits IMPDH & induces apoptosis-related biomarkers in patients with hematologic cancers":
- AVN944 inhibits IMPDH and induces apoptosis-related biomarkers in patients with hematologic cancers
12-11-2006 · EurekAlert!
IMPDH is highly upregulated in most hematological cancers and solid tumors -- an essential role in cancer cell synthesis of DNA and RNA. Inhibition of IMPDH represents a new and important approach to treat cancer. In a Phase I trial of AVN944, AvalonRx identified a set of 34 genes. These gene markers correlate with the biochemical effects of AVN944 on protein function -- believed to result in tumor cell apoptosis at the right doses.
Similar news · Read more »
- Gene patenting -- steep cost for health care and patients
05-07-2007 · EurekAlert!
The drug trastuzumab (Herceptin) is used to treat HER2-positive breast cancer (a type of breast cancer that overexpresses the HER2 gene and accounts for about 25 percent of all breast cancers). Trastuzumab therapy improves the chances of survival; however, it has deleterious side effects and is expensive. Thus, it is important to accurately determine the patient's HER2 status.
Similar news · Read more »
- New biomarker test could predict outcome for bladder cancer patients
02-01-2007 · EurekAlert!
A set of molecular biomarkers might better predict the recurrence of bladder cancer than conventional prognostic features such as the stage or grade of the malignancy at the time it is discovered, UT Southwestern Medical Center researchers have found.
Similar news · Read more »
- Modifying an anti-cancer drug makes it more specific
12-03-2007 · EurekAlert!
Imatinib is used to treat chronic myeloid leukemia and gastrointestinal stromal tumors because they are caused by related proteins. However, this lack of specificity means imatinib also affects normal bodily functions and it has been reported to have a toxic effect on the heart in some patients. Now, researchers have modified imatinib so it inhibits the protein behind GISTs but neither inhibits the protein behind CML nor has toxic effects on the mouse heart.
Similar news · Read more »
- New biomarker test could predict outcome for bladder cancer patients
02-01-2007 · UT Southwestern Medical Center
A set of molecular biomarkers might better predict the recurrence of bladder cancer than conventional prognostic features such as the stage or grade of the malignancy at the time it is discovered, UT Southwestern Medical Center researchers have found.
Similar news · Read more »
- Study calculates patient time costs associated with cancer care
01-02-2007 · EurekAlert!
In 2005, the overall cost of patients' time spent on cancer care was $2.3 billion in the first year after diagnosis, according to a new study in the Jan. 3 issue of the Journal of the National Cancer Institute. The time costs for the 11 cancers studied and for different phases of cancer care varied widely, they write.
Similar news · Read more »
- 3-D radiation treatment planning reduces feeding-tube use
11-05-2006 · EurekAlert!
Although current surgical techniques and multi-modality treatment regimens allow organ preservation for a growing number of patients with head and neck cancers, remaining dependent on a feeding tube after treatment is a major problem for these patients. An analysis by Fox Chase Cancer Center researchers sought to identify which treatment-related factors are more likely to avoid feeding-tube dependency.
Similar news · Read more »
- Natural protein stops deadly human brain cancer in mice
12-07-2006 · EurekAlert!
Scientists from Johns Hopkins and from the University of Milan have effectively proven that they can inhibit lethal human brain cancers in mice using a protein that selectively induces positive changes in the activity of cells that behave like cancer stem cells. The report is published this week in Nature.
Similar news · Read more »
- Genes and biomarkers that allow doctors to choose the right therapy for the right patient
04-17-2007 · EurekAlert!
Genetic and epigenetic variations ensure that no two people are exactly alike, and the same holds true for any two cancers. Now, researchers have the tools and the knowledge to help predict how individuals will respond to cancer therapies, enabling them to create more effective therapies for individual cancers -- personalized medicine.
Similar news · Read more »
- UCLA researchers discover biomarkers that predict lung cancer patient response to therapy
01-31-2008 · EurekAlert!
Researchers at UCLA's Jonsson Cancer Center have discovered biomarkers that predict which patients with advanced non-small cell lung cancer will respond to a combination treatment of the anti-inflammatory drug Celebrex and the growth factor receptor blocker Tarceva.
Similar news · Read more »
